The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

Author： Ma Brigette   Lui Vivian   Hui Edwin   Lau Cecilia   Ho Kakiu   Ng Margaret   Cheng S.   Tsao Sai-Wah   Chan Anthony  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.28, Iss.4, 2010-08, pp. : 413-420

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

By Wong Chi   Loong Herbert   Hui Connie   Lau Cecilia   Hui Edwin   Ma Brigette   Chan Anthony  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1399-1408

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite

Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

By  

Current Clinical Pharmacology, Vol. 6, Iss. 3, 2011-08 ,pp. : 214-221

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma

By  

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 126-142

Bentham Science Publishers

Access to resources Recommend Favorite

Everolimus [RAD 001], in combination with octreotide long-acting repeatable (LAR), shows promising antitumour activity

By  

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite